Findings showed 100% of participants taking the tobevibart and elebsiran combination achieved an undetectable HDV RNA at week 24 that was sustained through week 60. The Food and Drug Administration ...
CEO Marianne De Backer emphasized Vir's progress in advancing its infectious disease and oncology programs. Key milestones include initiating the ECLIPSE Phase III registrational program for hepatitis ...
The Nation (PK) on MSN
Health ministry, DRAP to combat hepatitis delta virus through global collaboration
The Ministry of National Health Services, Regulations and Coordination, in collaboration with the Drug Regulatory Authority of Pakistan (DRAP), has taken a step toward addressing the growing challenge ...
– Positive, updated Phase 2 SOLSTICE data showed combination of tobevibart and elebsiran is well tolerated and achieved undetectable HDV RNA in 88% of chronic hepatitis delta participants evaluable at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results